Overcoming regulatory and economic challenges facing pharmacogenomics

New Biotechnology

Volumn 29, Issue 6, 2012, Pages 751-756

  Cohen, Joshua P ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL DEVELOPMENT; CLINICAL PRACTICE GUIDELINES; CLINICAL UTILITY; ECONOMIC BARRIERS; ECONOMIC CHALLENGES; HUMAN GENOME PROJECT; MARKET PLACE; PERSONALIZED MEDICINES; PHARMACOGENOMICS; REGULATORY GUIDANCE; REGULATORY PROCESS;

INFORMATION DISSEMINATION;

PROGRAM DIAGNOSTICS;

ABACAVIR; B RAF KINASE; BCR ABL PROTEIN; CETUXIMAB; CHEMOKINE RECEPTOR CCR5; CRIZOTINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IPILIMUMAB; IRINOTECAN; MARAVIROC; TRASTUZUMAB; WARFARIN;

ARTICLE; BREAST CANCER; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DISEASE PREDISPOSITION; DRUG DEVELOPMENT; GENOTYPE; HEALTH CARE POLICY; HOSPITALIZATION; HUMAN; IMMUNOCHEMISTRY; LEUKEMIA; MEDICARE; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; REIMBURSEMENT; UNITED STATES;

DRUG INDUSTRY; HEALTH POLICY; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; SOCIAL CONTROL, FORMAL;

EID: 84865438507     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2012.02.001     Document Type: Article

References (35)

1. Tucker L (2008): Pharmacogenomics: A Primer for Policymakers. National Health Policy Forum. (accessed 01.10.11). http://www.nhpf.org/library/background-papers/BP_Pharmacogenomics_01-28-08.pdf.
2. Wong W., et al. Cost effectiveness of pharmacogenomics. Pharmacoeconomics 2010, 28:1001-1013.
3. Giaccone G. The role of gefitinib in lung cancer treatment. Clin. Cancer Res. 2004, 10:4233s-4237s.
4. Deverka P. Pharmacogenomics, evidence, and the role of payers. Pub. Health Gen. 2009, 12:149-157.
5. Phillips K. The intersection of biotechnology and pharmacogenomics: health policy implications. Health Aff. 2006, 25:1271-1280.
6. Tanisha C., et al. Medicare's coverage of colorectal cancer drugs: a case study in evidence development and policy. Health Aff. 2009, 25:1231-1239.
7. Tufts Cost-Effectiveness Analysis Registry (2011). (accessed 21.10.11). https://research.tufts-nemc.org/cear4/.
8. Khoury M., et al. The evidence dilemma in genomic medicine. Health Aff. 2008, 27:1600-1611.
9. Meckley L., Neumann P. Personalized medicine: factors influencing reimbursement. Health Pol. 2010, 94:91-100.
10. Personalized Medicine Coalition (2009). The Case for Personalized Medicine. (accessed 21.10.11). http://www.personalizedmedicinecoalition.org/sites/default/files/TheCaseforPersonalizedMedicine_5_5_09.pdf.
11. Kitamura M. Bristol-Myers Skin-Cancer Drug Yervoy Rejected by U.K. Health Cost Agency. (accessed 24.10.11). http://www.bloomberg.com/news/2011-10-13/bristol-myers-s-skin-cancer-drug-rejected-by-u-k-cost-agency.html.
12. Institute of Medicine (2001): Crossing the Quality Chasm: A New Health System for the 21st Century. (accessed 23.10.11). http://www.iom.edu/Reports/2001/Crossing-the-Quality-Chasm-A-New-Health-System-for-the-21st-Century.aspx.
13. Lesko L., Woodcock J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat. Rev. Drug Discov. 2004, 3:763-769.
14. Paci D., Ibarreta D. Economic and cost-effectiveness considerations for pharmacogenetics tests: an integral part of translational research and innovation uptake in personalized medicine. Curr. Pharmacogen. Pers. Med. 2009, 7:284-296.
15. Frueh F., et al. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 2008, 28:992-998.
16. FDA's Table of Valid Genomic Biomarkers: (accessed 01.09.11). http://www.fda.org/cder/genomics/genomic_biomarkers_table.htm.
17. Piccart-Gebhart M., et al. Trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N. Engl. J. Med. 2005, 352:1659-1672.
18. Romond E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2 positive breast cancer. N. Engl. J. Med. 2005, 353:1673-1684.
19. Deverka P., et al. Economic opportunities and challenges for pharmacogenomics. Annu. Rev. Pharmacol. Toxicol. 2010, 50:423-437.
20. Mallal S., et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 2008, 358:568-579.
21. Wang L., et al. Genomics and drug response. N. Engl. J. Med. 2011, 364:1144-1153.
22. Hamburg M., Collins F. The path to personalized medicine. N. Engl. J. Med. 2010, 363:301-304.
23. FDA seeks comment on proposed policy for diagnostic tests used with targeted drug therapies. (accessed 01.09.11). http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm262632.htm.
24. Bouchie A. Companion test case. Biocentury 2011, 19:A1.
25. Chustecka Z (2010). Crizotinib in ALK-NSCLC; response rate 'unprecedented.' Medscape Medical News; June 7. (accessed 13.07.11). http://www.medscape.com/viewarticle/723075.
26. Cohen J, Manzolillo K, Wilson A. Clinical and economic challenges facing pharmacogenomics. Pharmacogen. J. (in press). http://www.nature.com/doifinder/10.1038/tpj.2011.63.
27. Epstein R., Russell Teagarden J. Comparative effectiveness research and personalized medicine. Pharmacoeconomics 2010, 28:905-913.
28. Decision Memo for Pharmacogenomic Testing for Warfarin Response (CAG-00400N) (2009). (accessed 12.10.11). https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx%3FNCAId=224%26ver=15%26NcaName=Pharmacogenomic+Testing+for+Warfarin+Response%26NCDId=333%26ncdver=1%26IsPopup=y%26bc=AAAAAAAAIAAA%26.
29. Gold H., et al. Cost-effectiveness of pharmacogenomics testing for UGT1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 2009, 115:3858-3867.
30. Final report of the Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS) (2006): Coverage and Reimbursement of Genetic Tests and Services. (accessed 30.09.11). http://oba.od.nih.gov/oba/sacghs/reports/CR_slides_Feb2006.pdf.
31. Randall T. Pfizer's Crizotinib Wipes Out Rare Lymphoma in Two Test Cases. (accessed 21.09.11). http://www.bloomberg.com/news/2011-02-23/pfizer-s-crizotinib-wipes-out-rare-lymphoma-in-two-test-cases.html.
32. Danzon P., Taylor E. Drug pricing and value in oncology. Oncologist 2010, 15(Suppl 1):24-31.
33. Chernew M., et al. Trends in patient cost sharing for clinical services used as quality indicators. J. Gen. Intern. Med. 2010, 25:243-248.
34. Chambers J., Neumann P. Listening to Provenge - what a costly cancer treatment says about future Medicare policy. N. Engl. J. Med. 2011, 364:1687-1689.
35. Lung cancer (non-small-cell, first line) - gefitinib. National Institute of Health and Clinical Excellence. (accessed 05.10.11). http://www.nice.org.uk/.